Reaction
Subcutaneous Emphysema reporting signals
As of the last recalculation, Subcutaneous Emphysema appears in 970 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is REMDESIVIR (PRR 55.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Remdesivir | 33 | 55.0 | 55.1 |
| Bleomycin Sulfate | 23 | 48.9 | 49.0 |
| Rocuronium Bromide | 20 | 37.2 | 37.2 |
| Sevoflurane | 12 | 31.4 | 31.4 |
| Liothyronine Sodium | 11 | 27.4 | 27.4 |
| Ganciclovir Sodium | 13 | 26.7 | 26.7 |
| Norepinephrine | 12 | 24.4 | 24.4 |
| Basiliximab | 13 | 24.0 | 24.1 |
| Propofol | 35 | 21.3 | 21.3 |
| Cefepime | 14 | 21.2 | 21.3 |
| Ganciclovir | 10 | 21.2 | 21.2 |
| Norepinephrine Bitartrate | 14 | 21.2 | 21.2 |
| 0Xygen | 46 | 21.0 | 21.0 |
| Oxygen | 46 | 21.0 | 21.0 |
| Cefepime Hydrochloride | 14 | 18.9 | 18.9 |
| Prednisolone | 134 | 18.3 | 18.3 |
| Prednisolone Oral | 134 | 18.3 | 18.3 |
| Prednisolone Oral Solution | 134 | 18.3 | 18.3 |
| Midazolam | 20 | 17.4 | 17.4 |
| Midazolam Hydrochloride | 20 | 16.3 | 16.3 |
| Meropenem | 22 | 15.0 | 15.0 |
| Imatinib | 12 | 14.8 | 14.8 |
| Nintedanib | 19 | 13.2 | 13.2 |
| Abemaciclib | 6 | 6.5 | 6.5 |
| Pirfenidone | 10 | 5.3 | 5.3 |